KR970705981A - 약제(Medicaments) - Google Patents
약제(Medicaments)Info
- Publication number
- KR970705981A KR970705981A KR1019970702014A KR19970702014A KR970705981A KR 970705981 A KR970705981 A KR 970705981A KR 1019970702014 A KR1019970702014 A KR 1019970702014A KR 19970702014 A KR19970702014 A KR 19970702014A KR 970705981 A KR970705981 A KR 970705981A
- Authority
- KR
- South Korea
- Prior art keywords
- surfactant
- composition
- integer
- hydrogen
- formula
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 4
- 239000004094 surface-active agent Substances 0.000 claims abstract 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract 8
- 239000001257 hydrogen Substances 0.000 claims abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 8
- 239000003380 propellant Substances 0.000 claims abstract 7
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract 6
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- -1 beclomethasone ester Chemical class 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 239000003979 granulating agent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000640 hydroxylating effect Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 229960005018 salmeterol xinafoate Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
입상 약제, 플루오로카본 또는 수소-함유 클로로플루오로카본 추진제 및 화학식(I)의 계면활성제로 이루어지는 제약적 에어로졸 조성물에 관한 것이다.
식 중, n은 1 내지 18의 정수이고, m은 0 내지 17의 정수이며, R1, R2및 R3는 각각 독립적으로 수소 원자 또는 C1-4알칼기이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (28)
- 입상 약제, 플루오로카본 또는 수소-함유 클로로플루오로카본 초진제 및 화학식(Ia) 또는 (Ib)의 계면활성제로 이루어지는 제약적 에어로졸 조성물.식 중, R1은 RF(CH2)a-(CH=CH)b-(CH2)C-(CH=CH)d-(CH2)e-A-, RF(CH2)f-OCH2CH(CH2OH)-A-, RF(CH2)g-OCH2CH(CH2OH)-A-, RF-(CH2-CH2-O)h-, RF-(CH(CH3)CH2O)h- 또는 RF-(CH2-S)h-이고; [여기서, -A-는 -O-, -C(O)O-, -R6(R7)N+-여기서, R6및 R7은 각각 C1-C4알킬 또는 히드록시에틸임), -(CH2)t-(여기서, t는 0또는 1임) 또는 -C(O)N(R9)-(CH2)q-B (여기서, q는 0 내지 12의 정수이고, B는 -0- 또는 -C(O)-이며, R9는 수소 는 R6임)이고, a+c+e의 합계는 0 내지 17이며, b+d의 합계는 0 내지 12이고, f 및 g는 각각 1내지 12이며, h는 1내지 12이고, RF는 하기 구조들중 어느 하나를 갖는 불소 함유 잔기이다: (a)F(CF2)i-(여기서, i는 1내지 18임), (b) (CF3)2CF(CF2)j-(여기서, j는 0 내지 8임), (c) RF1(CF2CF(CF3))k-(여기서, K는 1내지 4이고, RF1은 CF3-,C2F5- 또는 (CF3)2CF-임), (d) RF2(RF3)CFO(CF2CF2)ℓ- (여기서, ℓ은 1내지 6이고, RF2 및 RF3는 각각 독립적으로 CF3-, C2F5-, n-C3F7- 또는 CF3CF2CF(CF3)-이거나 또는 RF2및 RF3가 함께 -(CF2)4- 또는 -(CF2)5- 를 형성함), 또는 (e) 구조 (a) 내지 (d)에 있어서, RF의 탄소 골격에 결합되어 있는 원자의 적어도 50%가 불소원자가 되도록 하는 비율로 1개 이상의 불소 원자가 1개 이상의 수소 또는 브롬 원자 및(또는) 적어도 2개의염소 원자로 치환되고, RF가 적어도 4개의 불소 원자를 함유하는 구조] r은 0 또는 1이며 ; R2는 R1, 수소 또는 OR기이고; (여기서, R은 포화되거나 또는 포화되지 않은 C1-C20알킬 또는 C3-C20아실이고 r이 1일 때 R1및 R2는 이들의 위치를 서로 바꿀 수 있음) X 및 Y는 각각 독립적으로 히드록실, -OCH2CH(OH)CH2OH, -O(CH2CH2O)tR3, -NR4R5또는 N+R4R5R8, -O(CH2)pZ이며, [여기서, t는 1내지 5의 정수이고, R3는 수소원자 또는 C1-C4알킬기이며, R4-R5및 R8은 각각 독립적으로 수소 원자, C1-C4알킬기 또는 -CH2CH2O(CH2CH2O)sR3(여기서 s는 1내지 5의 정수임)이거나, 또는 R4및 R5가 함께 - (CH2)q(여기서, q는 2 내지 5의 정수임)을 형성하거나, 또는 R4및 R5가 질소원자와 함께 모르폴리노기를 형성하며, Z는 2-아미노아세트산기, -NR4R5또는 -N+R4R5R8이고 (여기서, R8은 상기 R4및 R5에 대해 정의한 바와 같음), p는 1내지 5의 정수임] 단, X 및 Y가 둘다 히드록실이거나 또는 히드록실로부터 유도된 이온화 형태를 갖지는 않는다.
- 입상 약제, 플루오로카본 또는 수소-함유 클로로플루오카본 추진제 및 화학식(I)의 계면 활성제로 이루어지는 제약적 에어로졸 조성물.식 중, n은 1내지 18의 정수이고, m은 0 내지 17의 정수이며, R1, R2, 및 ,R3는 각각 독립적으로 수소 원자 또는 C1-4알킬기이다.
- 제2항에 있어서, R1, R2및 R3가 각각 메틸인 조성물.
- 제2항 또는 제3항에 있어서, n이 4 내지 8의 정수인 조성물.
- 제4항에 있어서, n이 4 또는 6인 조성물.
- 제2항 내지 제5항 중 어느 한 항에 있어서, m이 4내지 10의 정수인 조성물.
- 제6항에 있어서, m이 4, 6 또는 10인 조성물.
- 제1항 내지 제7항 중 어느 한 항에 있어서, 계면활성제가 약제에 대해 0.05 내지 15% w/w의 양으로 존재하는 조성물.
- 제8항에 있어서, 계면활성제가 약제에 대해 0.5 내지 10% w/w의 양으로 존재하는 조성물.
- 제1항 내지 제9항 중 어느 한 항에 있어서, 약제의 입도가 1~10 미크론범위인 조성물.
- 제1항 내지 제10항 중 어느 한 항에 있어서, 약제가 조성물의 총 중량에 대하여 0.01~1.0% w/w의 양으로 존재하는 조성물.
- 제1항 내지 제11항 중 어느 한항에 있어서, 입상 약제가 크로모글리케이트, 살부타몰, 살메테롤, 테르부탈린, 레프로테롤, 베클로메타손 에스테르, 플루티카손 에스테르 및 (-)-4-아미노-3, 5-디클로로-α-[[[6-[2-(2-피리디닐)에톡시]헥실]아니노]메틸]벤젠메탄올로 이루어진 군에서 선택되는 조성물.
- 제12항에 있어서, 입상 약제가 살메테롤 크시나포에이트, 살부타몰, 플루티카손 프로피오네이트, 베클로메타손 디프로피오네이트 및 그의 생리적으로 혀용되는 염 및 용해화물로 이루어진 군에서 선택되는 조성물.
- 제2항 내지 제13항 중 어느 한 항에 있어서, (a) 0 유효량의 입상 기관지 확장제, (b) 유효량의 입상 항염증제, (c) 플루오로카본 또는 수소-함유 클로로플루오로카본 추진제, 및 (d) 화학식(I)의 계면활성제로 이루어지는 조성물.
- 제1항 내지 제 14항 중 어느 한 항에 있어서, 상기 추진제가 C1-4수소-함유플루오로카본으로 이루어지는 조성물.
- 제15항에 있어서, 상기 추진제가 1, 1, 1, 2-테트라플루오로에탄(CF3CH2F) 및 1, 1, 1, 2, 3, 3, 3-헵타플루오로-n-프로판(CF3CHFCF3)에서 선택되는 조성물.
- 제2항 내지 제16항 중 어느 한 항에 있어서, 1종 이상의 입상 약제, 1종 이상의 플루오로카본 또는 수소-함유 클로로플루오로카본 추진제 및 화학식(I)의 계면활성제를 주성분으로 하는 조성물.
- 화학식(I)의 계면활성제.식 중, n은 1내지 18의 정수이고, m은 0내지 17의 정수이며, R1, R2및 R3는 각각 독립적으로 수소 원자 또는 C1-4알칼기이되, 단 n이 4일 m은 4가 아니다.
- 제18항에 있어서, R1, R2및 R3가 각각 메틸인 계면활성제.
- 제18항 또는 제19항에 있어서, n이 4 내지 8의 정수인 계면활성제.
- 제20항에 있어서, n이 4 또는 6인 계면활성제.
- 제18항 내지 제21항 중 어느 한 항에 있어서, m이 4 내지 10의 정수인 계면활성제.
- 제22항에 있어서, m이 4, 6 또는 10인 계면활성제.
- 제1항 내지 제17항 중 어느 한 항에 따른 조성물의 유효량을 흡입에 의해 투여하는 것으로 이루어지는 호흡 장애의 치료 방법.
- 상기 약제 및 계면활성제를 상기 추진제 중에 분산시키는 것으로 이루어지는 제1항 내지 제17항 중 어느한 항에 따른 조성물의 제조 방법.
- 화학식(Ⅱ)의 화합물을 (ⅰ) 화학식(Ⅲ)의 화합물, 및 (ⅱ) 히드록실화제와 반응시키는 것으로 이루어지는 제18항 내지 제 23항 중 어느 한 항에 따른 게면 활성제의 제조 방법.식 중, Hal은 불소, 염소, 브롬 및 요오드로부터 선택되는 할로겐 원자이다.식 중, L은 음으로 하전된 카운터 이온이다.
- 실질적으로 본 명세서에 기재된 바와 같은 제약적 에어로졸 조성물.
- 실질적으로 본 명세서에 기재된 바와 같은 화학식(I)의 계면활성제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9419536.9 | 1994-09-28 | ||
| GB9419536A GB9419536D0 (en) | 1994-09-28 | 1994-09-28 | Medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970705981A true KR970705981A (ko) | 1997-11-03 |
| KR100375469B1 KR100375469B1 (ko) | 2003-10-17 |
Family
ID=10762008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970702014A KR100375469B1 (ko) | 1994-09-28 | 1995-09-27 | 약제 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5849265A (ko) |
| EP (1) | EP0783302B1 (ko) |
| JP (1) | JPH10506887A (ko) |
| KR (1) | KR100375469B1 (ko) |
| CN (1) | CN1084614C (ko) |
| AP (1) | AP742A (ko) |
| AT (1) | ATE187063T1 (ko) |
| AU (1) | AU707922B2 (ko) |
| BG (1) | BG62839B1 (ko) |
| BR (1) | BR9509108A (ko) |
| CZ (1) | CZ286356B6 (ko) |
| DE (1) | DE69513671T2 (ko) |
| DK (1) | DK0783302T3 (ko) |
| EE (1) | EE03380B1 (ko) |
| ES (1) | ES2140706T3 (ko) |
| FI (1) | FI971279A (ko) |
| GB (1) | GB9419536D0 (ko) |
| GE (1) | GEP20002140B (ko) |
| GR (1) | GR3032245T3 (ko) |
| HU (1) | HU221856B1 (ko) |
| IS (1) | IS1991B (ko) |
| MD (1) | MD1900C2 (ko) |
| MX (1) | MX9702149A (ko) |
| NO (1) | NO313658B1 (ko) |
| NZ (1) | NZ292995A (ko) |
| OA (1) | OA10603A (ko) |
| PL (1) | PL181453B1 (ko) |
| RO (1) | RO118564B1 (ko) |
| RU (1) | RU2157188C2 (ko) |
| SK (1) | SK281519B6 (ko) |
| UA (1) | UA47412C2 (ko) |
| WO (1) | WO1996009816A1 (ko) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
| US6039932A (en) * | 1996-09-27 | 2000-03-21 | 3M Innovative Properties Company | Medicinal inhalation aerosol formulations containing budesonide |
| US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| ATE233084T1 (de) * | 1999-04-14 | 2003-03-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung |
| US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
| GB0009606D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| US6451287B1 (en) | 2000-05-26 | 2002-09-17 | Smithkline Beecham Corporation | Fluorinated copolymer surfactants and use thereof in aerosol compositions |
| GB0016876D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
| IL154175A0 (en) * | 2000-08-05 | 2003-07-31 | Glaxo Group Ltd | 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| US6858593B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777400B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US7217409B2 (en) | 2000-09-22 | 2007-05-15 | Smithkline Beecham Corporation | Alkanoic acid derivatives |
| GB0106046D0 (en) | 2001-03-12 | 2001-05-02 | Glaxo Group Ltd | Canister |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| AU2002253342B2 (en) * | 2001-04-30 | 2007-01-04 | Glaxo Group Limited | Novel anti-inflammatory androstane derivatives |
| ATE399174T1 (de) * | 2001-06-12 | 2008-07-15 | Glaxo Group Ltd | Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen |
| GB0118364D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Compounds |
| JP2005501082A (ja) * | 2001-08-03 | 2005-01-13 | グラクソ グループ リミテッド | 界面活性剤化合物およびその使用 |
| GB0125127D0 (en) | 2001-10-19 | 2001-12-12 | Glaxo Group Ltd | Compounds |
| US6702997B2 (en) | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| JP2003221335A (ja) | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
| US20030203930A1 (en) * | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| US20030191151A1 (en) * | 2001-10-26 | 2003-10-09 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| US20030140920A1 (en) * | 2001-10-26 | 2003-07-31 | Dey L.P. | Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| US7217833B2 (en) | 2002-02-13 | 2007-05-15 | Glaxco Group Limited | Carboxylic acid compounds for use as surfactants |
| GB0205327D0 (en) * | 2002-03-06 | 2002-04-17 | Glaxo Group Ltd | compounds |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| EP2275479A1 (en) | 2003-08-11 | 2011-01-19 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
| CN1874756B (zh) | 2003-08-29 | 2012-02-29 | 葛兰素集团有限公司 | 药用计量剂量吸入器和其相关方法 |
| US7030255B2 (en) * | 2004-03-09 | 2006-04-18 | Lyondell Chemical Technology, L.P. | Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor |
| EP1949891A1 (en) | 2004-10-12 | 2008-07-30 | Generics (UK) Limited | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
| US9808423B2 (en) * | 2004-10-12 | 2017-11-07 | Generics [Uk] Limited | Preparation of suspension aerosol formulations |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| US8148377B2 (en) | 2007-02-11 | 2012-04-03 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile |
| GB0712454D0 (en) * | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352789A (en) * | 1980-03-17 | 1982-10-05 | Minnesota Mining And Manufacturing Company | Aerosol compositions containing finely divided solid materials |
| GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DE69002767T2 (de) * | 1989-06-22 | 1994-03-17 | Atta | Fluor- und phosphorhaltige amphiphilische moleküle mit oberflächenaktiven eigenschaften. |
| GB8921222D0 (en) * | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| DE69109284T2 (de) * | 1990-03-23 | 1995-08-24 | Minnesota Mining & Mfg | Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe. |
| WO1992000062A1 (en) * | 1990-06-27 | 1992-01-09 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
-
1994
- 1994-09-28 GB GB9419536A patent/GB9419536D0/en active Pending
-
1995
- 1995-09-27 DE DE69513671T patent/DE69513671T2/de not_active Expired - Fee Related
- 1995-09-27 BR BR9509108A patent/BR9509108A/pt not_active IP Right Cessation
- 1995-09-27 AP APAP/P/1997/000951A patent/AP742A/en active
- 1995-09-27 MD MD97-0134A patent/MD1900C2/ro not_active IP Right Cessation
- 1995-09-27 CN CN95196444A patent/CN1084614C/zh not_active Expired - Fee Related
- 1995-09-27 SK SK393-97A patent/SK281519B6/sk unknown
- 1995-09-27 RU RU97106511/14A patent/RU2157188C2/ru not_active IP Right Cessation
- 1995-09-27 HU HU9702260A patent/HU221856B1/hu not_active IP Right Cessation
- 1995-09-27 EE EE9700061A patent/EE03380B1/xx not_active IP Right Cessation
- 1995-09-27 JP JP8511571A patent/JPH10506887A/ja not_active Ceased
- 1995-09-27 GE GEAP19953636A patent/GEP20002140B/en unknown
- 1995-09-27 DK DK95932166T patent/DK0783302T3/da active
- 1995-09-27 US US08/809,764 patent/US5849265A/en not_active Expired - Fee Related
- 1995-09-27 EP EP95932166A patent/EP0783302B1/en not_active Expired - Lifetime
- 1995-09-27 KR KR1019970702014A patent/KR100375469B1/ko not_active IP Right Cessation
- 1995-09-27 RO RO97-00561A patent/RO118564B1/ro unknown
- 1995-09-27 ES ES95932166T patent/ES2140706T3/es not_active Expired - Lifetime
- 1995-09-27 AT AT95932166T patent/ATE187063T1/de not_active IP Right Cessation
- 1995-09-27 PL PL95319342A patent/PL181453B1/pl not_active IP Right Cessation
- 1995-09-27 UA UA97031255A patent/UA47412C2/uk unknown
- 1995-09-27 MX MX9702149A patent/MX9702149A/es not_active IP Right Cessation
- 1995-09-27 CZ CZ1997936A patent/CZ286356B6/cs not_active IP Right Cessation
- 1995-09-27 WO PCT/IB1995/000866 patent/WO1996009816A1/en active IP Right Grant
- 1995-09-27 NZ NZ292995A patent/NZ292995A/xx unknown
- 1995-09-27 AU AU35321/95A patent/AU707922B2/en not_active Ceased
-
1997
- 1997-03-10 IS IS4438A patent/IS1991B/is unknown
- 1997-03-21 OA OA60982A patent/OA10603A/en unknown
- 1997-03-21 BG BG101347A patent/BG62839B1/bg unknown
- 1997-03-25 NO NO19971422A patent/NO313658B1/no unknown
- 1997-03-26 FI FI971279A patent/FI971279A/fi not_active Application Discontinuation
-
1999
- 1999-12-22 GR GR990403333T patent/GR3032245T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970705981A (ko) | 약제(Medicaments) | |
| RU97106511A (ru) | Фармацевтическая аэрозольная композиция, способ изготовления такой композиции, способ лечения респираторных заболеваний, поверхностно-активное вещество для таких композиций и способ его получения | |
| DE69233150T2 (de) | Fluorchlorkohlenwasserstoffreie Aerosolformulierungen | |
| EP0653205B1 (en) | Non-chloroflurocarbon aerosol formulations | |
| US7601336B2 (en) | Pharmaceutical aerosol composition | |
| KR100546239B1 (ko) | 약제 에어로졸 조성물 | |
| US5376359A (en) | Method of stabilizing aerosol formulations | |
| JPH05505824A (ja) | 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用 | |
| CA2125667A1 (en) | Fluorocarbon aerosol medicaments | |
| KR970704422A (ko) | 투여용 약제학적 조성물 | |
| PT1133277E (pt) | Composição farmacológica de aerosol contendo hfa 227 e hfa 134a | |
| IE83747B1 (en) | Non-chlorofluorocarbon aerosol formulations | |
| BG64268B1 (bg) | Л...кар''в...ни а...розолни прод"к'и | |
| JP2004509159A (ja) | 新規なアルカン酸誘導体 | |
| PT94292A (pt) | Processo para a preparacao de uma composicao farmaceutica sob a forma de um aerossol contendo derivados de compostos macrociclicos | |
| CL2004001325A1 (es) | Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas. | |
| JP4223954B2 (ja) | 界面活性剤として使用するための化合物 | |
| US7390796B2 (en) | Fatty acid modified forms of glucocorticoids | |
| AU774250B2 (en) | Pharmaceutical aerosol composition | |
| HRP920381A2 (en) | Non-chlorofluorocarbon aerosol formulations | |
| JP2004503505A (ja) | 医薬用抗炎症エアゾール製剤 | |
| HRP920362A2 (en) | Non-chlorofluorocarbon aerosol formulations | |
| SI9400222A (sl) | Formulacije aerosolov brez klorofluoroogljikov |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| N231 | Notification of change of applicant | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080110 Year of fee payment: 6 |
|
| LAPS | Lapse due to unpaid annual fee |